4/A: Castle Biosciences Director Discloses Indirect Holdings in Amended SEC Filing

Daniel Bradbury, a director at Castle Biosciences, amended a previous SEC filing to include indirect holdings of common stock held in trusts and an LLC.

Summary

• Daniel Bradbury, a director of Castle Biosciences, filed an amendment to a Form 4 initially filed on May 29, 2024.
• The amendment, filed on July 16, 2024, includes indirect holdings of Castle Biosciences common stock that were previously omitted.
• These holdings include 9,981 shares held by the Annette Bradbury Irrevocable Descendant's Trust, 35,123 shares held by BioBrit, LLC, and 9,981 shares held by the Daniel Bradbury Irrevocable Descendant's Trust.
• Bradbury and his spouse are trustees of the descendant's trusts, with their children as beneficiaries.
• Bradbury is the managing member of BioBrit, LLC, and has voting and investment power over the shares held by the LLC.

Sentiment

Score: 7

Explanation: The document is a routine regulatory filing. The sentiment is neutral as it simply discloses information about stock ownership. The amendment suggests a minor oversight that has been corrected.

Industry Context

This filing is a routine disclosure related to insider holdings and is required by the SEC to ensure transparency in the market.

Key Dates